Survival status, follow-up, and use of FLT3 inhibitors by individual patients among treatments. Follow-up, including survival status and treatment and follow-up periods, is shown for individual patients in the (A) AZA alone and (B) GIL + AZA groups who received subsequent AML therapy with FLT3 inhibitors.